ScreenerHero

HCWB HCW Biologics Inc.

NAS · US · Healthcare · Biotechnology · hcwbiologics.com
1.560USD-0.64%Mkt Cap: 3.49M $P/E: —

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products includ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.49M USD
Enterprise Value8.70M USD
Revenue (TTM)6.72M USD
Gross Profit10.85K USD
Net Income (TTM)-7.96M USD
Revenue/Share8.53 USD
Last Price1.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.85
PEG—
EV/EBITDA-1.56
EV/Revenue1.29
P/S0.52
P/B0.34
EPS (TTM)-19.17
EPS (Forward)-0.55
52W Range
1.5000% of range29.28
52W High29.28 USD
52W Low1.500 USD
Profitability
Gross Margin20.00%
Oper. Margin-2335.57%
EBITDA Margin-83.09%
Profit Margin-14677.14%
ROE-287.90%
ROA-32.46%
Growth
Revenue Growth1969.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.39M USD
CapEx (TTM)—
FCF Margin-173.50%
FCF Yield-334.26%
Net Debt5.82M USD
Net Debt/EBITDA-1.04
Balance Sheet
Debt/Equity2.46
Current Ratio0.06
Quick Ratio0.04
Book Value/Sh4.59 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 30, 2026
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)48.00 USD
Upside (mean)+2976.9%
Target Range48.00 USD – 48.00 USD
# Analysts1
Ownership
Shares Out.2.24M
Float1.65M
Insiders7.98%
Institutions7.41%
Short Interest
Short Ratio0.0d
Short % Float0.53%
Short % Out.0.51%
Shares Short9.27K
Short (prev mo.)14.35K
Technical
SMA 502.550 (-38.8%)
SMA 2004.745 (-67.1%)
Beta2.42
S&P 52W Chg16.45%
Avg Vol (30d)664.60K
Avg Vol (10d)1.48M
Technical Indicators
RSI (14)30.9
MACD-0.3496
MACD Signal-0.3680
MACD Hist.+0.0185
BB Upper2.524 USD
BB Middle1.924 USD
BB Lower1.324 USD
BB Width62.34%
ATR (14)0.2792 USD
Vol Ratio (20d)0.03x